---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-023054"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:00:35.153250+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma concludes Q3 2025 financials unreliable; total assets surge 179% to $21.06M

## Summary
- Board determined Q3 2025 financials unreliable due to revenue recognition errors ($795,950 reversed) and land valuation error ($798,486 increase).
- Company will restate Q3 2025 10-Q; identifies material weakness in internal controls over financial reporting.
- FY2025 total assets $21.06M (179% YoY); property/equipment $12.84M (up from $0.51M).
- Strategic land acquisitions in Taiwan valued at ~$4.6M (Longtan) and ~$8.0M (Puli) strengthen asset base.
- Revenue and EPS not disclosed; licensing model retains economics while reducing cash burn.

## SEC filing metadata
- accession: 0001213900-26-023054
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390026023054/0001213900-26-023054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390026023054/ea0279143-8k_abvc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-023054
- JSON: https://secwatch.observer/filing/0001213900-26-023054.json
- Plain text: https://secwatch.observer/filing/0001213900-26-023054.txt

## Source-grounded claims
- claim_id: c492adde7e5659a7ace29ae5a63b8e8bcf150d3c
  claim: ABVC BIOPHARMA, INC. reported that prior financial statements should not be relied upon.
  evidence_excerpt: atters disclosed in this Item 4.02 with its independent registered public accounting firm, Simon & Edward, LLP. Due to the above, the Company determined that it has a material weakness in its internal controls over financial reporting and shall include such determination in its Annual Report on Form
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390026023054/0001213900-26-023054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.